|
|
| (97 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| | __NOTOC__ | | __NOTOC__ |
| | *'''[[Further reading]]''' | | *'''[[Further reading]]''' |
| | + | |
| | | | |
| | *'''[[Unproven ideas]]''' | | *'''[[Unproven ideas]]''' |
| − | {{tp|p=32311318|t=ä. SARS-CoV-2 and ''viral sepsis'': observations and hypotheses |pdf=|usr=}}
| |
| − | {{tp|p=32325026|t=2020. Endothelial cell infection and endotheliitis in COVID-19 |pdf=|usr=}}
| |
| | | | |
| | *'''[[Reviews on covid19 disease]]''' | | *'''[[Reviews on covid19 disease]]''' |
| − | {{tp|p=32363726|t=2020. The Novel Coronavirus - Latest Findings |pdf=|usr=}}
| + | *'''[[Clinical guidelines and advice]]''' |
| − | {{tp|p=32144890|t=2020. The Novel Coronavirus ? A Snapshot of Current Knowledge |pdf=|usr=}}
| + | |
| − | {{tp|p=32032682|t=ä. Pathogenicity and transmissibility of 2019-nCoV?A quick overview and comparison with other emerging viruses |pdf=|usr=}}
| + | |
| − | {{tp|p=32017984|t=2020. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32226946|t=ä. COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we don?t |pdf=|usr=}}
| + | |
| − | {{tp|p=32169119|t=2020. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak ? an update on the status |pdf=|usr=}}
| + | |
| − | {{tp|p=32297723|t=2020. COVID-2019: update on epidemiology, disease spread and management |pdf=|usr=}}
| + | |
| − | {{tp|p=32188753|t=2020. COVID-19: Knowns, Unknowns, and Questions |pdf=|usr=}}
| + | |
| − | {{tp|p=32109013|t=ä. Clinical Characteristics of Coronavirus Disease 2019 in China |pdf=|usr=}}
| + | |
| − | {{tp|p=31978945|t=2020. A Novel Coronavirus from Patients with Pneumonia in China, 2019 |pdf=|usr=}}
| + | |
| − | {{tp|p=32342126|t=ä. COVID-19: A primer for Neuroradiologists |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | | | |
| − | *'''[[Clinical guidelines and advice]]''' | + | *'''[[Respiration mgmt]]''' |
| − | {{tp|p=C7155395|t=ä. German recommendations for critically ill patients with COVID?19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32166350|t=ä. Empfehlungen zur intensivmedizinischen Therapie von Patienten mit COVID-19 |pdf=|usr=}}
| + | *'''[[Diagnosis (Laboratory)]]''' |
| − | {{tp|p=32029004|t=2020. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) |pdf=|usr=}}
| + | |
| − | {{ttp|p=32307014|t=2020. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19 |pdf=|usr=}}
| + | |
| | + | *'''[[Diagnosis (Lung CT, Sonography)]]''' |
| | + | |
| | + | *'''[[Diagnosis (other modalities)]]''' |
| | | | |
| | | | |
| − | ----
| |
| | | | |
| | | | |
| | *'''[[Structure of covid19]]''' | | *'''[[Structure of covid19]]''' |
| − | {{tp|p=32350227|t=2020. Characteristics of SARS-CoV-2 isolated from asymptomatic carrier in Tokyo |pdf=|usr=}}
| + | |
| − | {{tp|p=32007145|t=2020. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding |pdf=|usr=}}
| + | |
| − | {{tp|p=32342926|t=2020. Properties of Coronavirus and SARS-CoV-2 |pdf=|usr=}}
| + | |
| − | {{tp|p=32194253|t=ä. Molecular basis of COVID-19 relationships in different species: a one health perspective |pdf=|usr=}}
| + | |
| − | {{tp|p=32302675|t=ä. Comparative computational analysis of SARS-CoV-2 nucleocapsid protein epitopes in taxonomically related coronaviruses |pdf=|usr=}}
| + | |
| − | {{tp|p=32165386|t=2020. Complete Genome Sequence of a 2019 Novel Coronavirus (SARS-CoV-2) Strain Isolated in Nepal |pdf=|usr=}}
| + | |
| − | {{ttp|p=32289821|t=ä. Extreme genomic CpG deficiency in SARS-CoV-2 and evasion of host antiviral defense |pdf=|usr=}}
| + | |
| − | {{tp|p=32371472|t=2020. SARS-CoV-2 and ORF3a: Nonsynonymous Mutations, Functional Domains, and Viral Pathogenesis |pdf=|usr=}}
| + | |
| − | {{tp|p=32123347|t=ä. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 |pdf=|usr=}}
| + | |
| − | {{tp|p=32303698|t=ä. A map of SARS-CoV-2 and host cell interactions |pdf=|usr=}}
| + | |
| | | | |
| | *'''[[Target binding and uptake]]''' | | *'''[[Target binding and uptake]]''' |
| − | {{tp|p=32199943|t=ä. Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{ttp|p=32362314|t=ä. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells |pdf=|usr=}}
| |
| − | {{tp|p=32221306|t=2020. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV |pdf=|usr=}}
| |
| − | {{tp|p=32094589|t=ä. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses |pdf=|usr=}}
| |
| − |
| |
| | *'''[[Cytopathic effects]]''' | | *'''[[Cytopathic effects]]''' |
| − |
| |
| | *'''[[Secretion and shedding]]''' | | *'''[[Secretion and shedding]]''' |
| − | {{tp|p=32304647|t=2020. SARS-CoV-2 shedding and infectivity |pdf=|usr=}}
| |
| − | {{tp|p=32304646|t=ä. SARS-CoV-2 shedding and infectivity ? Authors reply |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 60: |
Zeile 34: |
| | | | |
| | *'''[[Immunology]]''' | | *'''[[Immunology]]''' |
| − | {{tp|p=32259560|t=ä. Interleukin-6 as a potential biomarker of COVID-19 progression |pdf=|usr=}}
| |
| − | {{ttp|p=32092539|t=2020. Is COVID-19 receiving ADE from other coronaviruses?|pdf=|usr=}}
| |
| − | {{tp|p=32268188|t=ä. It is too soon to attribute ADE to COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32361001|t=ä. Bioinformatic analysis and identification of single-stranded RNA sequences recognized by TLR7/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes |pdf=|usr=}}
| |
| − | {{ttp|p=32305501|t=ä. The Potential Role of Th17 Immune Responses in Coronavirus Immunopathology and Vaccine-induced Immune Enhancement |pdf=|usr=}}
| |
| − | {{tp|p=32248387|t=ä. Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of Caution |pdf=|usr=}}
| |
| − | {{tp|p=32321823|t=2020. COVID-19: an Immunopathological View |pdf=|usr=}}
| |
| − | {{tp|p=32284614|t=ä. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32273594|t=ä. COVID-19: immunopathology and its implications for therapy |pdf=|usr=}}
| |
| − | {{tp|p=32249845|t=ä. Fighting COVID-19 exhausts T cells |pdf=|usr=}}
| |
| − | {{tp|p=32355329|t=ä. SARS-CoV-2-reactive T cells in patients and healthy donors |pdf=|usr=}}
| |
| − | {{ttp|p=32355328|t=ä. Impaired interferon signature in severe COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32346093|t=ä. The trinity of COVID-19: immunity, inflammation and intervention |pdf=|usr=}}
| |
| − | {{tp|p=32346091|t=ä. Neutralizing antibody response in mild COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32303697|t=ä. Will we see protection or reinfection in COVID-19?|pdf=|usr=}}
| |
| − | {{tp|p=32303696|t=ä. Macrophages: a Trojan horse in COVID-19?|pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' |
| | | | |
| | | | |
| | | | |
| − | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' | + | *'''[[Pathobiology]]''' |
| − | {{tp|p=32353251|t=ä. COVID-19 cytokine storm: the interplay between inflammation and coagulation |pdf=|usr=}}
| + | |
| − | {{tp|p=32339596|t=ä. Predictive factors of poor outcomes in the COVID-19 epidemic: Consider the inflammatory response |pdf=|usr=}}
| + | |
| − | {{tp|p=32249847|t=ä. In the eye of the COVID-19 cytokine storm |pdf=|usr=}}
| + | |
| | | | |
| − | ----
| + | |
| | + | *'''[[Disease Models]]''' |
| | + | |
| | + | |
| | + | *'''[[Similar diseases and pathomechanisms]]''' |
| | | | |
| | | | |
| Zeile 95: |
Zeile 55: |
| | | | |
| | *'''[[Co-Infection]]''' | | *'''[[Co-Infection]]''' |
| − | {{tp|p=32307254|t=ä. Invasive fungal diseases during COVID-19: We should be prepared |pdf=|usr=}}
| |
| − | {{tp|p=32297939|t=ä. SARS-CoV-2 and Legionella Co-infection in a Person Returning from a Nile Cruise |pdf=|usr=}}
| |
| − | {{tp|p=32293646|t=ä. Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens |pdf=|usr=}}
| |
| | | | |
| − |
| |
| − | *'''[[ARDS]]'''
| |
| | | | |
| | *'''[[Pulmonary embolism, coagulation]]''' | | *'''[[Pulmonary embolism, coagulation]]''' |
| − | {{tp|p=32330428|t=ä. Hospital-based use of thromboprophylaxis in patients with COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32268022|t=ä. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19 |pdf=|usr=}}
| + | |
| | + | |
| | | | |
| | | | |
| | *'''[[Hematology]]''' | | *'''[[Hematology]]''' |
| − | {{tp|p=32294340|t=ä. Immune Thrombocytopenic Purpura in a Patient with Covid-19 |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | *'''[[Microvascular]]'''
| |
| | | | |
| | *'''[[Heart]]''' | | *'''[[Heart]]''' |
| − | {{tp|p=32334650|t=ä. Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes |pdf=|usr=}}
| |
| − | {{tp|p=32360126|t=2020. Myocardial injury and COVID-19: Possible mechanisms |pdf=|usr=}}
| |
| − | {{tp|p=32302081|t=ä. ST-Segment Elevation in Patients with Covid-19 ? A Case Series |pdf=|usr=}}
| |
| − | {{tp|p=32319272|t=2020. COVID-19 and cardiovascular disorder |pdf=|usr=}}
| |
| − | {{tp|p=32340429|t=2020. The role of natriuretic peptide estimation in severe COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32348640|t=ä. Out-of-Hospital Cardiac Arrest during the Covid-19 Outbreak in Italy |pdf=|usr=}}
| |
| − | {{tp|p=32139904|t=ä. COVID-19 and the cardiovascular system |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| | *'''[[Neurology, ophthalmology, orl]]''' | | *'''[[Neurology, ophthalmology, orl]]''' |
| − | {{tp|p=32305563|t=ä. Features of anosmia in COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32302082|t=ä. Guillain-Barre Syndrome Associated with SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32294339|t=ä. Neurologic Features in Severe SARS-CoV-2 Infection |pdf=|usr=}}
| |
| − | {{tp|p=32350026|t=2020. Guillain-Barre syndrome related to COVID-19 infection |pdf=|usr=}}
| |
| − | {{tp|p=32346843|t=ä. Neurological Implications of COVID-19 Infections |pdf=|usr=}}
| |
| − | {{tp|p=32364120|t=ä. PACIENTE CON CLINICA NEUROLOGICA COMO UNICA MANIFESTACION DE INFECCION POR SARS-CoV-2. |pdf=|usr=}}
| |
| − | {{tp|p=32364123|t=ä. Sindrome de Guillain Barre asociado a infeccion por SARS-CoV-2. |pdf=|usr=}}
| |
| − | *[ Sindrome de Guillain-Barre fatal tras infeccion por el virus SARS-CoV-2. Neurology 2020. PMID 32376041 PMID: 32376041 was deleted because it is a duplicate of PMID: 32364124]
| |
| − | {{tp|p=32364121|t=ä. Infeccion por SARS-CoV-2 asociada a diplopia y anticuerpos antirreceptor de acetilcolina |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| | *'''[[Dermatology]]''' | | *'''[[Dermatology]]''' |
| | + | |
| | | | |
| | | | |
| | *'''[[Gastroenterology, hepatology]]''' | | *'''[[Gastroenterology, hepatology]]''' |
| − | {{tp|p=32336473|t=ä. COVID-19 y aparato digestivo |pdf=|usr=}}
| |
| − | {{tp|p=32240876|t=2020. Hyperglycemia and the novel Covid-19 infection: Possible pathophysiologic mechanisms |pdf=|usr=}}
| |
| − | {{tp|p=32342369|t=2020. Wie das Coronavirus den Magen-Darm-Trakt angreift: Seminar / Gastromodul |pdf=|usr=}}
| |
| | | | |
| | *'''[[Kidney, urology]]''' | | *'''[[Kidney, urology]]''' |
| − | {{tp|p=32273593|t=ä. Kidney involvement in COVID-19 and rationale for extracorporeal therapies |pdf=|usr=}}
| |
| − | {{tp|p=32313110|t=ä. The need for urogenital tract monitoring in COVID-19 |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[The morbid survivor]]''' |
| | | | |
| − | ----
| + | *'''[[Risk and special populations]]''' |
| | | | |
| | | | |
| − | *'''[[Pathobiology]]'''
| |
| − | {{tp|p=32243911|t=ä. C-reactive protein levels in the early stage of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32291399|t=ä. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies |pdf=|usr=}}
| |
| − | {{tp|p=32249846|t=ä. Dysregulation of lung myeloid cells in COVID-19 |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Case reports]]''' |
| | | | |
| | | | |
| − | *'''[[Disease Models]]'''
| |
| | | | |
| − | *'''[[Similar diseases and pathomechanisms]]'''
| |
| − | {{tp|p=32370951|t=ä. Missed or Delayed Diagnosis of Kawasaki Disease During the 2019 Novel Coronavirus Disease (COVID-19) Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32341622|t=2020. SARS-CoV-2: Camazotz s Curse |pdf=|usr=}}
| |
| − | {{tp|p=32246819|t=2020. Pulmonary High-Resolution Computed Tomography (HRCT) Findings of Patients with Early-Stage Coronavirus Disease 2019 (COVID-19) in Hangzhou, China |pdf=|usr=}}
| |
| − | {{tp|p=32358574|t=ä. 100 years of influenza research seen through the lens of Covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32372197|t=ä. New challenges from Covid-19 pandemic: an unexpected opportunity to enlighten the link between viral infections and brain disorders?|pdf=|usr=}}
| |
| − | {{tp|p=32323862|t=2020. What can Parkinson s disease teach us about COVID-19?|pdf=|usr=}}
| |
| | | | |
| − | ----
| |
| | | | |
| | | | |
| − | *'''[[Diagnosis (Laboratory)]]'''
| |
| − | {{tp|p=32333644|t=2020. RT-LAMP for rapid diagnosis of coronavirus SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32183357|t=2020. 2019 Novel Coronavirus Disease (COVID-19): Paving the Road for Rapid Detection and Point-of-Care Diagnostics |pdf=|usr=}}
| |
| − | {{tp|p=32106462|t=2020. Disposable DNA Amplification Chips with Integrated Low-Cost Heaters ? |pdf=|usr=}}
| |
| − | {{tp|p=32074444|t=2020. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Case series]]''' |
| | | | |
| − |
| |
| − | *'''[[Diagnosis (Lung CT, Sonography)]]'''
| |
| − | {{tp|p=32367213|t=ä. CT-Verlauf einer Coronavirus(2019-nCoV)-Pneumonie |pdf=|usr=}}
| |
| − | {{tp|p=32358406|t=2020. COVID-19 with cystic features on computed tomography: A case report |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − | *'''[[Diagnosis (other modalities)]]'''
| |
| − | {{tp|p=32344326|t=2020. COVID-19 and malaria: A symptom screening challenge for malaria endemic countries |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | *'''[[Respiration mgmt]]'''
| |
| − | {{tp|p=32336080|t=2020. Extracorporeal membrane oxygenation for critically ill patients with coronavirus-associated disease 2019: an updated perspective of the European experience |pdf=|usr=}}
| |
| − | {{tp|p=32236089|t=2020. Respiratory physiotherapy in patients with COVID-19 infection in acute setting: a Position Paper of the Italian Association of Respiratory Physiotherapists (ARIR) |pdf=|usr=}}
| |
| − | {{tp|p=32268719|t=2020. Intubation and mechanical ventilation of patients with COVID-19: what should we tell them?|pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − | *'''[[Risk and special populations]]'''
| |
| − | {{tp|p=32333196|t=2020. Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32271125|t=2020. Diabetes and the COVID-19 Pandemic: How Insights from Recent Experience Might Guide Future Management |pdf=|usr=}}
| |
| − | {{tp|p=32220612|t=2020. Diabetes patients with COVID-19 need better blood glucose management in Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32220611|t=2020. Commentary: COVID-19 in patients with diabetes |pdf=|usr=}}
| |
| − | {{tp|p=32275971|t=ä. COVID-19 in patients with diabetes: risk factors that increase morbidity |pdf=|usr=}}
| |
| − | {{tp|p=32360211|t=ä. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease |pdf=|usr=}}
| |
| − | {{tp|p=32360397|t=ä. Mechanisms of increased morbidity and mortality of SARS-CoV-2 infection in individuals with diabetes: what this means for an effective management strategy |pdf=|usr=}}
| |
| − | {{tp|p=32353356|t=ä. Obesity: the ?Achilles heel? for COVID-19?|pdf=|usr=}}
| |
| − | {{tp|p=32333939|t=2020. Importance of metabolic health in the era of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32333938|t=2020. Obesity hypoventilation syndrome and severe COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32320741|t=2020. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease |pdf=|usr=}}
| |
| − | {{tp|p=32320740|t=ä. Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32320742|t=ä. COVID-19 and diabetes mellitus: what we know, how our patients should be treated now, and what should happen next? |pdf=|usr=}}
| |
| − | {{tp|p=32271728|t=2020. Coronavirus Disease 2019 in Children - United States, February 12?April 2, 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32345328|t=2020. Analysis of the susceptibility of lung cancer patients to SARS-CoV-2 infection |pdf=|usr=}}
| |
| − | {{tp|p=32218613|t=ä. Coronaviruserkrankung bei Kindern ? erste Daten aus Wuhan |pdf=|usr=}}
| |
| − | {{ttp|p=32317808|t=ä. COVID-19 bei hospitalisierten Kindern und Jugendlichen: Ein systematischer Review zu publizierten Fallserien (Stand 31 03 2020) und erste Daten aus Deutschland |pdf=|usr=}}
| |
| − | {{tp|p=32339915|t=ä. Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32315980|t=2020. COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?|pdf=|usr=}}
| |
| − | {{tp|p=32348641|t=ä. Covid-19 in Immune-Mediated Inflammatory Diseases ? Case Series from New York |pdf=|usr=}}
| |
| − | {{tp|p=32187458|t=ä. SARS-CoV-2 Infection in Children |pdf=|usr=}}
| |
| − | {{tp|p=32163697|t=2020. Detection of Covid-19 in Children in Early January 2020 in Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32227760|t=ä. Renin?Angiotensin?Aldosterone System Inhibitors in Patients with Covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32302077|t=ä. Clinical Characteristics of Pregnant Women with Covid-19 in Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32237670|t=ä. An Uncomplicated Delivery in a Patient with Covid-19 in the United States |pdf=|usr=}}
| |
| − | {{tp|p=32265531|t=ä. COVID-19 and cancer: what we know so far |pdf=|usr=}}
| |
| − | {{tp|p=32346090|t=ä. Does asthma make COVID-19 worse?|pdf=|usr=}}
| |
| − | {{tp|p=32246101|t=ä. Controversies of renin?angiotensin system inhibition during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32358609|t=ä. The COVID-19 outbreak and the angiotensin-converting enzyme 2: too little or too much?|pdf=|usr=}}
| |
| − | {{tp|p=32222703|t=ä. COVID-19 Infection in a Patient with End-Stage Kidney Disease |pdf=|usr=}}
| |
| − | {{tp|p=32197096|t=ä. COVID-19 in pregnant women ? Authors reply |pdf=|usr=}}
| |
| − | {{tp|p=32283004|t=ä. Universal Screening for SARS-CoV-2 in Women Admitted for Delivery |pdf=|usr=}}
| |
| − | {{tp|p=32346676|t=ä. Crowdsourcing a crisis response for COVID-19 in oncology |pdf=|usr=}}
| |
| − | {{tp|p=32161408|t=2020. Lack of maternal?fetal SARS-CoV-2 transmission |pdf=|usr=}}
| |
| − | {{tp|p=32284613|t=ä. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding |pdf=|usr=}}
| |
| − | {{tp|p=32231328|t=ä. Interaction between RAAS inhibitors and ACE2 in the context of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32327737|t=ä. Obesity and impaired metabolic health in patients with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32203970|t=ä. Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade |pdf=|usr=}}
| |
| − | {{tp|p=32311696|t=ä. Comment on ?Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade? |pdf=|usr=}}
| |
| − | {{tp|p=32371550|t=2020. COVID-19 infection in a patient with multiple sclerosis treated with fingolimod |pdf=|usr=}}
| |
| − | {{tp|p=32303856|t=ä. Digital triage for people with multiple sclerosis in the age of COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32270359|t=ä. Acute stroke management pathway during Coronavirus-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32270358|t=ä. No lockdown for neurological diseases during COVID19 pandemic infection |pdf=|usr=}}
| |
| − | {{tp|p=32364125|t=ä. Consulta de epilepsia durante la pandemia de Covid-19: papel de la telemedicina y efectos del confinamiento en pacientes epil�pticos |pdf=|usr=}}
| |
| − | {{tp|p=32364122|t=ä. Neuroinfecciones en tiempos de COVID-19 |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − | *'''[[The morbid survivor]]'''
| |
| − | {{tp|p=32219356|t=ä. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32369030|t=2020. Considerations for Postacute Rehabilitation for Survivors of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32333842|t=2020. The key role of palliative care in response to the COVID-19 tsunami of suffering |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | *'''[[Case reports]]'''
| |
| − | {{tp|p=32224310|t=ä. Clinical and virological data of the first cases of COVID-19 in Europe: a case series |pdf=|usr=}}
| |
| − | {{tp|p=32164830|t=2020. COVID-19 with spontaneous pneumomediastinum |pdf=|usr=}}
| |
| − | {{tp|p=32229159|t=ä. SARS-CoV-2 infection presenting with hematochezia |pdf=|usr=}}
| |
| − | {{tp|p=32004427|t=2020. First Case of 2019 Novel Coronavirus in the United States |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − | *'''[[Case series]]'''
| |
| − | {{tp|p=32220650|t=ä. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study |pdf=|usr=}}
| |
| − | {{tp|p=32087116|t=2020. Asymptomatic cases in a family cluster with SARS-CoV-2 infection |pdf=|usr=}}
| |
| − | {{tp|p=32105632|t=ä. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study |pdf=|usr=}}
| |
| − | {{tp|p=32379729|t=2020. Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19 - Georgia, March 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32214079|t=2020. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32290644|t=2020. Clinical and epidemiologic profile of the initial COVID-19 patients at a tertiary care centre in India |pdf=|usr=}}
| |
| − | {{tp|p=32227758|t=ä. Covid-19 in Critically Ill Patients in the Seattle Region ? Case Series |pdf=|usr=}}
| |
| − | {{tp|p=32302078|t=ä. Clinical Characteristics of Covid-19 in New York City |pdf=|usr=}}
| |
| − | {{tp|p=32332185|t=2020. Care for adult non-ICU Covid-19 patients: early experiences from a Belgian tertiary care centre |pdf=|usr=}}
| |
| | | | |
| | *'''[[Registries]]''' | | *'''[[Registries]]''' |
| − | {{tp|p=32305438|t=ä. The AAD COVID-19 Registry: Crowdsourcing Dermatology in the Age of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32309814|t=ä. Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries |pdf=|usr=}}
| |
| − | {{tp|p=32242121|t=ä. The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | ----
| |
| | | | |
| | | | |
| | *'''[[Trials]]''' | | *'''[[Trials]]''' |
| − | {{tp|p=32290293|t=2020. A Review of SARS-CoV-2 and the Ongoing Clinical Trials |pdf=|usr=}}
| |
| − | {{tp|p=32363333|t=ä. A real-time dashboard of clinical trials for COVID-19 |pdf=|usr=}}
| |
| | | | |
| | *'''[[Candidate Compounds Covid19]]''' | | *'''[[Candidate Compounds Covid19]]''' |
| − | {{tp|p=C7158785|t=ä. Convalescent plasma: A possible treatment of COVID-19 in India |pdf=|usr=}}
| |
| − | {{tp|p=32217166|t=2020. Chloroquine and COVID-19, where do we stand?? |pdf=|usr=}}
| |
| − | {{tp|p=32240719|t=ä. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection |pdf=|usr=}}
| |
| − | {{tp|p=32353355|t=ä. Testosterone, a key hormone in the context of COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32344177|t=2020. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect |pdf=|usr=}}
| |
| − | {{tp|p=32305500|t=ä. Chloroquine paradox may cause more damage than help fight COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32370766|t=2020. Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines |pdf=|usr=}}
| |
| − | {{tp|p=32307014|t=2020. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32255312|t=2020. A possible probiotic (S salivarius K12) approach to improve oral and lung microbiotas and raise defenses against SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32365556|t=2020. Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-gamma as Candidates for Cytokine Storm Modulation in COVID-19 Disease |pdf=|usr=}}
| |
| − | {{tp|p=32316270|t=2020. COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help |pdf=|usr=}}
| |
| − | {{tp|p=32231349|t=2020. Chloroquine in COVID-19: the evidence |pdf=|usr=}}
| |
| − | {{tp|p=32231348|t=2020. Emerging prophylaxis strategies against COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32291351|t=2020. Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing Data |pdf=|usr=}}
| |
| − | {{tp|p=32187464|t=ä. A Trial of Lopinavir?Ritonavir in Adults Hospitalized with Severe Covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32187463|t=ä. Covid-19 ? The Search for Effective Therapy |pdf=|usr=}}
| |
| − | {{tp|p=32275812|t=ä. Compassionate Use of Remdesivir for Patients with Severe Covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32354113|t=2020. On Facing the SARS-CoV-2 (COVID-19) with Combination of Nanomaterials and Medicine: Possible Strategies and First Challenges |pdf=|usr=}}
| |
| − | {{tp|p=32326343|t=2020. Can Nanotechnology and Materials Science Help the Fight against SARS-CoV-2?|pdf=|usr=}}
| |
| − | {{tp|p=32366817|t=2020. A human monoclonal antibody blocking SARS-CoV-2 infection |pdf=|usr=}}
| |
| − | {{tp|p=32203437|t=ä. Insights from nanomedicine into chloroquine efficacy against COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32358580|t=ä. COVID-19: a case for inhibiting IL-17?|pdf=|usr=}}
| |
| − | {{tp|p=32358579|t=ä. Will helminth co-infection modulate COVID-19 severity in endemic regions?|pdf=|usr=}}
| |
| − | {{tp|p=32296135|t=ä. COVID-19: risk for cytokine targeting in chronic inflammatory diseases?|pdf=|usr=}}
| |
| − | {{tp|p=32355330|t=ä. Inactivated vaccine for SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32327719|t=ä. Complement as a target in COVID-19?|pdf=|usr=}}
| |
| − | {{tp|p=32346092|t=ä. Cancer therapy tool informs COVID-19 vaccines |pdf=|usr=}}
| |
| − | {{tp|p=32346094|t=ä. COVID-19 vaccine design: the Janus face of immune enhancement |pdf=|usr=}}
| |
| − | {{tp|p=32317716|t=ä. The potential danger of suboptimal antibody responses in COVID-19 |pdf=|usr=}}
| |
| − | *[https://www.biorxiv.org/content/10.1101/2020.03.22.002386v3 A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing]
| |
| − | {{tp|p=32286538|t=ä. Human antibodies can neutralize SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32332922|t=ä. SARS-CoV-2 infection of kidney organoids prevented with soluble human ACE2 |pdf=|usr=}}
| |
| − | {{tp|p=32327746|t=ä. Translating IL-6 biology into effective treatments |pdf=|usr=}}
| |
| − | {{tp|p=32341531|t=ä. Could BCG be used to protect against COVID-19?|pdf=|usr=}}
| |
| − | {{tp|p=32291449|t=ä. ADAM17 inhibition may exert a protective effect on COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32350818|t=ä. Chloroquine-induced QTc prolongation in COVID-19 patients |pdf=|usr=}}
| |
| | | | |
| | | | |
| | + | *'''[[Other routes of infection]]''' |
| | | | |
| − | ----
| |
| | | | |
| − | *'''[[Remission, recurrence and persistence]]''' | + | *'''[[Biophysics of aerosols]]''' |
| − | {{tp|p=32303482|t=ä. Re-emergence of SARS-CoV2 in a discharged COVID-19 case |pdf=|usr=}}
| + | |
| − | {{tp|p=32299784|t=ä. How do we decide to de-isolate COVID-19 patients?|pdf=|usr=}}
| + | |
| − | {{tp|p=32105304|t=2020. Positive RT-PCR Test Results in Patients Recovered From COVID-19 |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | | | |
| − | *'''[[Other routes of infection]]'''
| |
| − | {{tp|p=32276848|t=ä. Prolonged viral shedding in feces of pediatric patients with coronavirus disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32224116|t=ä. Do children need a longer time to shed SARS-CoV-2 in stool than adults?|pdf=|usr=}}
| |
| − | {{tp|p=32035510|t=2020. 2019-nCoV transmission through the ocular surface must not be ignored |pdf=|usr=}}
| |
| − | {{tp|p=32199469|t=2020. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples |pdf=|usr=}}
| |
| − | {{tp|p=32214231|t=ä. COVID-19: faecal?oral transmission?|pdf=|usr=}}
| |
| − |
| |
| − | *'''[[Biophysics of aerosols]]'''
| |
| − | {{tp|p=32340347|t=2020. Airborne Transmission Route of COVID-19: Why 2 Meters/6 Feet of Inter-Personal Distance Could Not Be Enough |pdf=|usr=}}
| |
| − | {{tp|p=32360356|t=ä. Putting some context to the aerosolization debate around SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32294374|t=ä. Droplets and Aerosols in the Transmission of SARS-CoV-2 |pdf=|usr=}}
| |
| | | | |
| | *'''[[Passive protective equipment]]''' | | *'''[[Passive protective equipment]]''' |
| − | {{tp|p=32129805|t=2020. Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient |pdf=|usr=}}
| + | |
| − | {{tp|p=32203710|t=2020. Rational use of face masks in the COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32344688|t=2020. 3-D Printed Protective Equipment during COVID-19 Pandemic |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | *'''[[Running your hospital]]''' | | *'''[[Running your hospital]]''' |
| − | {{tp|p=32322988|t=ä. Umgang mit COVID-19 in der Notaufnahme: Erfahrungsbericht der interdisziplinären Notaufnahme des Universitätsklinikums Münster |pdf=|usr=}}
| |
| − | {{tp|p=32329322|t=2020. In considerations of robotic colorectal surgery within a COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32327626|t=2020. Management of inflammatory bowel disease during COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32225135|t=2020. Pathways for urology patients during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32202401|t=2020. Urology practice during COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32253371|t=2020. Impact of the COVID-19 pandemic on urology residency training in Italy |pdf=|usr=}}
| |
| − | {{tp|p=32368875|t=2020. Guide for Nuclear Medicine Applications During the COVID-19 Outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32210421|t=2020. COVID-19 in intensive care Some necessary steps for health care workers |pdf=|usr=}}
| |
| − | {{tp|p=32297490|t=2020. COVID-19 pandemic: what consequences for cardiac rehabilitation?|pdf=|usr=}}
| |
| − | {{tp|p=32278860|t=2020. Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge |pdf=|usr=}}
| |
| − | {{tp|p=32335508|t=2020. One Aspect of Coronavirus disease (COVID-19) Outbreak in Iran: High Anxiety among MS Patients |pdf=|usr=}}
| |
| − | {{tp|p=32334820|t=2020. The COVID-19 pandemic and the use of MS disease-modifying therapies |pdf=|usr=}}
| |
| − | {{tp|p=31986242|t=2020. Medical Journals and the 2019-nCoV Outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32329975|t=ä. Covid-19 and Kidney Transplantation |pdf=|usr=}}
| |
| − | {{tp|p=32242095|t=ä. Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32341524|t=ä. Cancer and COVID-19 ? potentially deleterious effects of delaying radiotherapy |pdf=|usr=}}
| |
| − | {{tp|p=32296166|t=ä. Provision of cancer care during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32214232|t=ä. Management of IBD during the COVID-19 outbreak: resetting clinical priorities |pdf=|usr=}}
| |
| − | {{tp|p=32249840|t=ä. Minimizing the risk of COVID-19 among patients on dialysis |pdf=|usr=}}
| |
| − | {{tp|p=32355296|t=ä. Combating physical inactivity during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32340751|t=ä. Manejo de la epidemia por coronavirus SARS-CoV-2 (Covid 19) en unidades de hemodialisis |pdf=|usr=}}
| |
| − | {{tp|p=32278616|t=ä. Recomendaciones en el manejo de la pandemia por coronavirus SARS-CoV-2 (Covid-19) en pacientes con trasplante renal |pdf=|usr=}}
| |
| − | {{tp|p=32348989|t=2020. Infection Control Measures for COVID-19 in the Labour Suite and Neonatal Unit |pdf=|usr=}}
| |
| − | {{tp|p=32335559|t=2020. Neonatal Resuscitation Where the Mother Has a Suspected or Confirmed Novel Coronavirus (SARS-CoV-2) Infection: Suggestion for a Pragmatic Action Plan |pdf=|usr=}}
| |
| − | {{tp|p=32325458|t=2020. COVID-19 and Neonatal Resuscitation |pdf=|usr=}}
| |
| − | {{tp|p=32196116|t=ä. Recommendations for the prevention, mitigation and containment of the emerging SARS-CoV-2 (COVID-19) pandemic in haemodialysis centres |pdf=|usr=}}
| |
| − | {{tp|p=32339235|t=ä. A Quantitative Framework for Modeling COVID-19 Risk During Adjuvant Therapy Using Published Randomized Trials of Glioblastoma in the Elderly |pdf=|usr=}}
| |
| − | {{tp|p=32289798|t=ä. Clinical Trials during the SARS-CoV-2 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32277236|t=ä. Urgent Considerations for the Neuro-oncologic Treatment of Patients with Gliomas During the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32319670|t=2020. Telemedicine in neurosurgery during the novel coronavirus (COVID-19) pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32363507|t=ä. Dealing with immune-mediated neuropathies during COVID-19 outbreak: practical recommendations from the task force of the Italian Society of Neurology (SIN), the Italian Society of Clinical Neurophysiology (SINC) and the Italian Peripheral Nervous System Association (ASNP) |pdf=|usr=}}
| |
| − | {{tp|p=32096116|t=2020. The Risk and Prevention of Novel Coronavirus Pneumonia Infections Among Inpatients in Psychiatric Hospitals |pdf=|usr=}}
| |
| − | {{tp|p=32361728|t=ä. Letter: The Resiliency of the Neurosurgeon in the Midst of COVID-19 Pandemic Storm: The Italian Experience From the Frontline |pdf=|usr=}}
| |
| − | {{tp|p=32358606|t=ä. Letter: Considerations for Performing Emergent Neurointerventional Procedures in a COVID-19 Environment |pdf=|usr=}}
| |
| − | {{tp|p=32336528|t=ä. La gesti�n de la asistencia neurol�gica en tiempos de la pandemia de COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32364119|t=ä. Influencia de la infecci�n SARS-CoV-2 sobre enfermedades neurodegenerativas y neuropsiqui�tricas: �una pandemia demorada?|pdf=|usr=}}
| |
| − | {{tp|p=32364117|t=ä. Un Servicio de Neurolog�a de un hospital terciario en la pandemia COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32355985|t=ä. Letter: Safety Instructions for Neurosurgeons During COVID-19 Pandemic Based on Recent Knowledge and Experience |pdf=|usr=}}
| |
| − | {{tp|p=32355982|t=ä. Letter: Back Pain and Accesses to Emergency Departments During COVID-19 Lockdown in Italy |pdf=|usr=}}
| |
| − | {{tp|p=32355962|t=ä. Letter: The Use of Absorbable Sutures in Neurosurgical Procedures in the Time of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32355961|t=ä. Letter: COVID-19 Impact on the Medical Student Path to Neurosurgery |pdf=|usr=}}
| |
| − | {{tp|p=32355949|t=ä. Letter: Neurosurgical Patients? Management During the COVID-19 Pandemic?An Institutional Report From an African Neurosurgical Center |pdf=|usr=}}
| |
| − | {{tp|p=32242901|t=ä. Letter: The Coronavirus Disease 2019 Global Pandemic: A Neurosurgical Treatment Algorithm |pdf=|usr=}}
| |
| − | {{tp|p=32347942|t=ä. Letter: Surgical Management of Brain Tumor Patients in the COVID-19 Era |pdf=|usr=}}
| |
| − | {{tp|p=32343340|t=ä. Letter: Neurosurgical Management of Spinal Pathology Via Telemedicine During the COVID-19 Pandemic: Early Experience and Unique Challenges |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | ----
| + | *'''[[Mental aspects of health professionals]]''' |
| | | | |
| − |
| |
| − | *'''[[Mental aspects of health professionals]]'''
| |
| − | {{tp|p=32035030|t=2020. The mental health of medical workers in Wuhan, China dealing with the 2019 novel coronavirus |pdf=|usr=}}
| |
| − | {{tp|p=32085839|t=2020. Mental health care for medical staff in China during the COVID-19 outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32291383|t=2020. Psychological Impact and Coping Strategies of Frontline Medical Staff in Hunan Between January and March 2020 During the Outbreak of Coronavirus Disease 2019 (COVID-19) in Hubei, China |pdf=|usr=}}
| |
| − | {{tp|p=32221635|t=ä. Umgang mit psychischer Belastung bei Gesundheitsfachkräften im Rahmen der Covid-19-Pandemie |pdf=|usr=}}
| |
| | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' | | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' |
| − | {{tp|p=32294078|t=2020. Comparison of the Indicators of Psychological Stress in the Population of Hubei Province and Non-Endemic Provinces in China During Two Weeks During the Coronavirus Disease 2019 (COVID-19) Outbreak in February 2020 |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | | | |
| | *'''[[Avoiding clinical medicine in other diseases]]''' | | *'''[[Avoiding clinical medicine in other diseases]]''' |
| − | {{tp|p=32283124|t=ä. Reduction in ST-Segment Elevation Cardiac Catheterization Laboratory Activations in the United States during COVID-19 Pandemic |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | *'''[[Occupational medicine, workplace security and status hygienicus]]''' | | *'''[[Occupational medicine, workplace security and status hygienicus]]''' |
| − | {{tp|p=32305069|t=ä. Protecting workers aged 60?69 years from COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32219471|t=ä. Mutterschutz ? auch im Zeitalter der Coronakrise |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| | *'''[[Economic aspects of the status hygienicus]]''' | | *'''[[Economic aspects of the status hygienicus]]''' |
| − | {{tp|p=32242087|t=ä. What the stock market tells us about the post-COVID-19 world |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| Zeile 433: |
Zeile 145: |
| | | | |
| | *'''[[Host, vector, one health, atmospheric aspects]]''' | | *'''[[Host, vector, one health, atmospheric aspects]]''' |
| − | {{tp|p=32236594|t=2020. Possibility of transmission through dogs being a contributing factor to the extreme Covid-19 outbreak in North Italy |pdf=|usr=}}
| |
| − | {{tp|p=31996413|t=2020. Discovery of Bat Coronaviruses through Surveillance and Probe Capture-Based Next-Generation Sequencing |pdf=|usr=}}
| |
| − | {{tp|p=32051570|t=2020. Novel coronavirus takes flight from bats?|pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Origin of Covid19]]''' | | *'''[[Origin of Covid19]]''' |
| − | {{tp|p=32376697|t=2020. An Extensive Meta-Metagenomic Search Identifies SARS-CoV-2-Homologous Sequences in Pangolin Lung Viromes |pdf=|usr=}}
| |
| − | {{tp|p=32284615|t=ä. The proximal origin of SARS-CoV-2 |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Epidemiology]]''' | | *'''[[Epidemiology]]''' |
| − | {{tp|p=32282789|t=2020. Public Health Interventions to Mitigate Early Spread of SARS-CoV-2 in Poland |pdf=|usr=}}
| |
| − | {{tp|p=32244041|t=2020. Shell disorder analysis predicts greater resilience of the SARS-CoV-2 (COVID-19) outside the body and in body fluids |pdf=|usr=}}
| |
| − | {{tp|p=32088333|t=2020. Lessons learned from the 2019-nCoV epidemic on prevention of future infectious diseases |pdf=|usr=}}
| |
| − | {{tp|p=32087334|t=2020. The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future |pdf=|usr=}}
| |
| − | {{tp|p=32278074|t=ä. Emergency response to the outbreak of COVID-19: the Korean case |pdf=|usr=}}
| |
| − | {{tp|p=32379733|t=2020. Public Health Response to the Initiation and Spread of Pandemic COVID-19 in the United States, February 24-April 21, 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32379731|t=2020. COVID-19 Among Workers in Meat and Poultry Processing Facilities - 19 States, April 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32352957|t=2020. Assessment of SARS-CoV-2 Infection Prevalence in Homeless Shelters - Four U S Cities, March 27-April 15, 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32134909|t=2020. Active Monitoring of Persons Exposed to Patients with Confirmed COVID-19 - United States, January-February 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32324720|t=2020. Cleaning and Disinfectant Chemical Exposures and Temporal Associations with COVID-19 ? National Poison Data System, United States, January 1, 2020?March 31, 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32298247|t=2020. Characteristics of Health Care Personnel with COVID-19 - United States, February 12-April 9, 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32265315|t=2020. 2019 Novel Coronavirus (COVID-19) Pandemic: Built Environment Considerations To Reduce Transmission |pdf=|usr=}}
| |
| − | {{tp|p=32003551|t=2020. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany |pdf=|usr=}}
| |
| − | {{tp|p=31995857|t=2020. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus?Infected Pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32329972|t=ä. Asymptomatic Transmission, the Achilles? Heel of Current Strategies to Control Covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32182409|t=ä. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 |pdf=|usr=}}
| |
| − | {{tp|p=32289214|t=ä. Spread of SARS-CoV-2 in the Icelandic Population |pdf=|usr=}}
| |
| − | *[https://www.thegatewaypundit.com/2020/05/key-stat-43-u-s-covid-19-deaths-come-0-6-population/ 130fold relativ risk in part of us population]
| |
| − | {{tp|p=32273611|t=ä. A framework for identifying regional outbreak and spread of COVID-19 from one-minute population-wide surveys |pdf=|usr=}}
| |
| − | {{tp|p=31988464|t=2020. China s response to a novel coronavirus stands in stark contrast to the 2002 SARS outbreak response |pdf=|usr=}}
| |
| − | {{tp|p=32284619|t=ä. On the responsible use of digital data to tackle the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32284618|t=ä. Digital technology and COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32322102|t=ä. Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy |pdf=|usr=}}
| |
| − | {{tp|p=32257511|t=2020. COVID-19 Pandemic: Public Health Implications in Nepal |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Failure of executive measures]]'''
| |
| | | | |
| | | | |
| − | {{tp|p=32221514|t=ä. How behavioural science data helps mitigate the COVID-19 crisis |pdf=|usr=}}
| + | |
| | + | |
| | + | *'''[[Remission, recurrence and persistence]]''' |
| | + | |
| | + | |
| | + | |
| | + | *'''[[Failure of executive measures]]''' |
| | ---- | | ---- |
| | + | *'''[[Failure of politics and public health guidance]]''' |
| | | | |
| | | | |
| | *'''[[Political abuse of Covid19]]''' | | *'''[[Political abuse of Covid19]]''' |
| − | {{tp|p=32203324|t=ä. COVID-19 and the crisis of national development |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| | *'''[[Lost people]]''' | | *'''[[Lost people]]''' |
| − | {{tp|p=32294342|t=ä. Death from Covid-19 of 23 Health Care Workers in China |pdf=|usr=}}
| + | |
| − | {{tp|p=32334040|t=ä. The fate of house cats during the COVID-19 pandemic |pdf=|usr=}}
| + | |
| | *'''[[Lost civilization]]''' | | *'''[[Lost civilization]]''' |
| | + | |
| | ---- | | ---- |
| | | | |
| | | | |
| | *'''[[History of covid19 exploration]]''' | | *'''[[History of covid19 exploration]]''' |
| − | {{tp|p=C7110433|t=ä. Coronaviren: von der banalen Erkältung zum schweren Lungenversagen: Chronologie einer Pandemie |pdf=|usr=}}
| + | *'''[[misc.]]''' |
| − | {{tp|p=32108160|t=2020. Emergence of a novel human coronavirus threatening human health |pdf=|usr=}}
| + | |
| − | {{tp|p=31988490|t=2020. Outbreak of a novel coronavirus |pdf=|usr=}}
| + | |
| − | {{tp|p=32015508|t=2020. A new coronavirus associated with human respiratory disease in China |pdf=|usr=}}
| + | |
| − | {{tp|p=32015507|t=2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | + | *'''[[Research tools]]''' |
| | | | |
| − | *'''[[misc.]]'''
| |
| − | {{tp|p=32203708|t=ä. COVID-19 outbreak: less stethoscope, more ultrasound |pdf=|usr=}}
| |
| − | {{tp|p=32192583|t=2020. COVID-19: delay, mitigate, and communicate |pdf=|usr=}}
| |
| − | {{tp|p=32344311|t=2020. 2019-nCoV-SARS-CoV-2 (COVID-19) infection: Cruc?al?ty of Fur?n and relevance w?th cancer |pdf=|usr=}}
| |
| − | {{tp|p=32360951|t=2020. The first Ramadan during COVID-19 pandemic: 1 8 billion Muslims should fast or not?|pdf=|usr=}}
| |
| − | {{tp|p=32368884|t=2020. Management of COVID-19: the risks associated with treatment are clear, but the benefits remain uncertain |pdf=|usr=}}
| |
| − | {{tp|p=C7144332|t=ä. On being human in the face of a pandemic |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Research tools]]'''
| |
| − | {{tp|p=C7118609|t=ä. NetNCSP: Nonoverlapping closed sequential pattern mining |pdf=|usr=}}
| |
| − | {{tp|p=32365567|t=2020. Lab-on-a-Chip Technologies for the Single Cell Level: Separation, Analysis, and Diagnostics |pdf=|usr=}}
| |
| | | | |
| − | *'''[[PrePrint scene''' | + | |
| − | *[https://prelights.biologists.com/ prelights]
| + | {{tp|p=27490990|t=2017. AVCpred: an integrated web server for prediction and design of antiviral compounds |pdf=|usr=}} |
| | + | {{tp|p=25040500|t=2014. Engineering large viral DNA genomes using the CRISPR?Cas9 system |pdf=|usr=}} |
| | + | |
| | + | |
| | + | *'''[[PrePrint scene]]''' |
| | + | |
| | | | |
| | *'''[[from the ads]]''' | | *'''[[from the ads]]''' |
| − | *[lifechemicals.com antiviral candidate drugs]
| + | |
| − | *[biomol.com assays cytokines general spectrum]
| + | |
| − | *[labospace.com custom single probe assay 400 possible cytokines and so on]
| + | |
| − | *[codexdna.com dna synthesis]
| + | |
| − | *[eclipsebio.com around rna]
| + | |
| − | *[btbemulsions.com freud adjuvant kit]
| + | |
| | *'''[[Current state of coviki.org]]''' | | *'''[[Current state of coviki.org]]''' |
| | + | *'''[[on-topic personal thoughts]]''' |
